HOST DEPENDENCY FACTORS AS TARGETS FOR ANTIVIRAL THERAPY
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Mar 24, 2015
filing date -
Mar 25, 2014
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention relates to inhibitor(s) or antagonist(s) of PADI4 (peptidyl arginine deiminase, type IV), PPARδ (peroxisome proliferator-activated receptor delta), GCKR (glucokinase regulatory protein), and/or P2X4R (purinergic receptor P2X, ligand-gated ion channel 4) for the use as anti-viral agent(s) as well as for the use in the prevention and/or treatment of infection(s) with virus(es) of the Flaviviridae family, such as Dengue virus and hepatitis C virus (HCV). The present invention further relates to pharmaceutical compositions or kits comprising said inhibitor(s)/antagonist(s) and methods of preventing and/or treating infection(s) with virus(es) of the Flaviviridae family. The present invention further relates to methods of screening for antiviral agent(s). The present invention relates to PADI4 (peptidyl arginine deiminase, type IV), PPARδ (peroxisome proliferator-activated receptor delta), GCKR (glucokinase regulatory protein), and/or P2X4R (purinergic receptor P2X, ligand-gated ion channel 4) for the use in diagnosis, prevention and/or treatment of infection(s) with virus(es) of the Flaviviridae family, preferably as targets for antiviral treatment or as screening targets.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully